GoodRx (NASDAQ:GDRX) Trading Up 9.4% – Here’s What Happened

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares rose 9.4% on Monday . The stock traded as high as $1.97 and last traded at $2.0450. Approximately 816,222 shares changed hands during trading, a decline of 74% from the average daily volume of 3,153,104 shares. The stock had previously closed at $1.87.

Wall Street Analyst Weigh In

Several analysts have commented on GDRX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GoodRx in a research note on Friday. Mizuho dropped their target price on GoodRx from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Friday. Citigroup decreased their price target on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a report on Friday, January 9th. The Goldman Sachs Group lowered their price objective on shares of GoodRx from $4.00 to $2.50 and set a “neutral” rating on the stock in a research report on Monday. Finally, Morgan Stanley cut their price objective on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.33.

GoodRx Stock Performance

The stock’s 50 day moving average price is $2.51 and its two-hundred day moving average price is $3.26. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $731.47 million, a price-to-earnings ratio of 24.17, a PEG ratio of 0.71 and a beta of 1.52.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The firm had revenue of $194.79 million for the quarter, compared to the consensus estimate of $193.27 million. During the same quarter in the previous year, the firm earned $0.09 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Institutional Trading of GoodRx

A number of institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of GoodRx by 124.4% in the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after buying an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in GoodRx by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock valued at $3,455,000 after acquiring an additional 54,783 shares during the last quarter. Jane Street Group LLC purchased a new position in GoodRx during the 1st quarter valued at about $370,000. Teacher Retirement System of Texas raised its position in GoodRx by 99.1% during the second quarter. Teacher Retirement System of Texas now owns 98,371 shares of the company’s stock worth $490,000 after acquiring an additional 48,966 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in GoodRx by 16.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock worth $8,324,000 after acquiring an additional 236,896 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.